They declared that it is difficult to predict tumor risk for patients with familial or sporadic Hirschsprung disease and that in combined MEN2A/Hirschsprung disease families RET gene testing, tumor screening, and prophylactic thyroidectomy are indicated as in MEN2A [11]. The gene discussed is RET; the disease is multiple endocrine neoplasia type 2A.